The cost-effectiveness of long-acting reversible contraceptive methods in the UK: Analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline

Human Reproduction

Volumn 23, Issue 6, 2008, Pages 1338-1345

  Mavranezouli, I ^a,b  

^a ROYAL COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cost effectiveness; Discontinuation; Economic modelling; Long acting reversible contraception

Indexed keywords

COPPER INTRAUTERINE DEVICE; ETONOGESTREL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; FEMALE; FEMALE STERILIZATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; INTERMETHOD COMPARISON; LONG ACTING REVERSIBLE CONTRACEPTION; MEDICAL LITERATURE; METHODOLOGY; PRACTICE GUIDELINE; PREGNANCY; PROBABILITY; STATISTICAL MODEL; UNITED KINGDOM;

EID: 44449151134     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/den091     Document Type: Article

References (66)

1. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 1998;58:99S-107S.
2. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
3. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50-54.
4. Bhathena RK. The long-acting progestogen-only contraceptive injections: an update. Br J Obstet Gynaecol 2001;108:3-8.
5. Bianchi-Demicheli F, Perrin E, Bianchi PG, Dumont P, Ludicke F, Campana A. Contraceptive practice before and after termination of pregnancy: a prospective study. Contraception 2003;67:107-113.
6. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 54. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK, 2007.
7. Canto de Cetina TE, Canto P, Ordonez LM. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 2001;63:143-146.
8. Chiou C-F, Trussell J, Reyes E, Knight K, Wallace J, Udani J, Oda K, Borenstein J. Economic analysis of contraceptives for women. Contraception 2003;68:3-10.
9. Colli E, Tong D, Penhallegon R, Parazzini F. Reasons for contraceptive discontinuation in women 30-39 years old in New Zealand. Contraception 1999;59:227-231.
10. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002a;28:73-77.
11. Cox M, Tripp J, Blacksell S, and the UK Family Planning Reproductive Health Research Network. Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002b;28:69-72.
12. Croxatto HB, Urbancsek J, Massai R, Bennink HC, van Beek A, and the Implanon Study Group. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Hum Reprod 1999;14:976-981.
13. Curtis KM, Mohllajee AP, Peterson HB. Regret following female sterilization at a younger age: a systematic review. Contraception 2006;73:205-210.
14. Curtis L, Netten A. Unit Costs of Health and Social Care 2005. University of Kent, Personal Social Services Research Unit, Cantenbury, UK. http://www.pssru.ac.uk/pdf/uc/uc2005/uc2005.pdf(accessed on 11 August, 2006), 2005.
15. Department of Health. General Medical Services. Revised fees and Allowances 2003-2004. Department of Health, London, UK. http://www.dh.gov. uk/assetRoot/04/06/63/81/04066381.PDF (accessed on 11 August, 2006), 2003.
16. Department of Health. Prescription Cost Analysis for England 2005. NHS Health and Social Care Information Centre London, UK. http://www.ic.nhs.uk/ pubs/prescostanalysis2005/final/file (accessed on 11 August, 2006), 2006a.
17. Department of Health. NHS reference costs 2005. Department of Health, London. http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT_ID=4133221&chk=TxHkqo (accessed on 11 August, 2006), 2006b.
18. Edwards JE, Moore A. Implanon. A review of clinical studies. Br J Fam Plann 1999;24(Suppl 4):3-16.
19. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHS Guidance (January 2004). The copper intrauterine device as long term contraception. J Fam Plann Reprod Health Care 2004a;30:29-42.
20. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHS Guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004b;30:99-109.
21. Flores JB, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet 2005;90:228-233.
22. Forrest JD. Epidemiology of unintended pregnancy and contraceptive use. Am J Obstet Gynecol 1994;170:1485-1489.
23. French RS, Cowan FM, Mansour DJA, Morris S, Procter T, Hughes D, Robinson A, Guillebaud J. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000;4:1-107.
24. Furlong L-A. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002;47:881-885.
25. Government Statistical Service for the Department of Health. Abortion Statistics, England and Wales: 2004. Statistical Bulletin 2005/11. Office for National Statistics, London, UK. http://www.dh.gov.uk/ PublicationsAndStatistics/Publications/PublicationsStatistics/ PublicationsStatisticsArticle/fs/en?CONTENT_ID=4116461&chk=6T9UTA (accessed on 3 August, 2006), 2005.
26. Grady W, Billy JOG, Klepinger DH. Contraceptive method switching in the United States. Perspect Sex Reprod Health 2002;34:135-145.
27. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-29.
28. Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception 1999;60:345-351.
29. Hurskainen R, Teperi J, Rissanen P, Aalto A-M, Grenman S, Kivelä A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. Clinical outcomes and costs with the levonorgestrel releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456-1463.
30. Ingelhammar E, Moller A, Svanberg B, Tornbom M, Lilja H, Hamberger L. The use of contraceptive methods among women seeking a legal abortion. Contraception 1994;50:143-152.
31. Koenig JD, Strauss MJ, Henneberry J, Wilson TG. The social costs of inadequate contraception. Int J Technol Assess Health Care 1996;12:487-497.
32. Lakha F, Glasier A. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception 2006a;74:287-289.
33. Lakha F, Glasier A. Unintended pregnancy and use of emergency contraception among a large cohort of women attending for antenatal care or abortion in Scotland. Lancet 2006b;368:1782-1787.
34. Lawlor DA, Ebrahim S, Smith GD. The association of socio-economic position across the life course and age at menopause: the British Women's Heart and Health Study. Br J Obstet Gynaecol 2003;110:1078-1087.
35. Lei ZW, Wu SC, Garceau RJ, Jiang S, Yang QZ, Wang WL, Vander Meulen TC. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 1996;53:357-361.
36. Macdowall W, Gerressu M, Nanchahal K, Wellings K. Analysis of Natsal 2000 Data for Wales. A Report to the National Assembly for Wales. http://www.cmo.wales.gov.uk/content/work/sexualhealth/natsal-2000-e.pdf (accessed on 11 August, 2006), 2002.
37. McGuire A, Hughes D. The economics of family planning services. A report prepared for the Contraceptive Alliance. Family Planning Association, Contraceptive Alliance, London, UK, 1995.
38. National Collaborating Centre for Women's and Children's Health. Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception. Commissioned by the National Institute for Health and Clinical Excellence. London: RCOG Press. http:www.nice.org. uk/pdf/CG030fullguideline.pdf (accessed on 3 August, 2006), 2005.
39. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. National Institute for Clinical Excellence, London, UK. 2004.
40. National Institute for Health and Clinical Excellence. The Guidelines Manual. National Institute for Health and Clinical Excellence, London, UK, 2006.
41. O'Sullivan I, Keyse I, Park N, Diaper A, Short S. Contraception and Sexual Health, 2004/05. Office for National Statistics, London, UK, http://www.statistics.gov.uk/downloads/theme_health/Contraception2004.pdf (accessed on 3 August, 2006), 2005.
42. Office for National Statistics. Birth Statistics. Review of the Registrat General on births and patterns of family building in England and Wales 2004. Series FM1, No 33. Office for National Statistics, London, UK. http://www.statistics.gov.uk/statbase/Product.asp?vlnk=5768 (accessed on 18 August, 2006), 2005.
43. Office for National Statistics. Table 01: United Kingdom; estimated resident population by single year of age and sex; Mid-2005 Population Estimates. Office for National Statistics, London, UK, http://www.statistics. gov.uk/statbase/ssdataset.asp?vlnk=9387&More=Y (accessed on 17 August, 2006), 2006.
44. Paul C, Skegg DCG, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception 1997;56:209-214.
45. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussel J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1161-1168.
46. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussel J, for the U.S. Collaborative Review of Sterilization Working Group. The risk of ectopic pregnancy after tubal sterilization. N Engl J Med 1997;336:762- 767.
47. Phillips CJ. Economic analysis of long term reversible contraceptives: focus on Implanon. Pharmacoeconomics 2000;17:209-221.
48. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-582.
49. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89-92.
50. Rosenberg MJ, Waugh MS, Meehan E. Use and misuse of oral contraceptives: risk indicators for poor pill taking and early discontinuation. Contraception 1995;51:283-288.
51. Rowlands S, Hannaford P. The incidence of sterilisation in the UK. Br J Obstet Gynaecol 2003;110:819-824.
52. Royal College of Obstetricians and Gynaecologists. Male and Female Sterilisation: Evidence-based Clinical Guideline Number 4. London, UK: RCOG Press, 2004.
53. Scottish Office. Scottish National Statistics 2005. Scottish Statistics, Glaskow, UK. http://www.isdscotland.org (accessed on 3 August, 2006), 2005.
54. Scottish Programme for Clinical Effectiveness in Reproductive Health. Scottish Audit of the Management of Early Pregnancy Loss. SPCERH publication no. 19. Scottish Programme for Clinical Effectiveness in Reproductive Health, Aberdeen, UK, 2003.
55. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291-298.
56. Sonnenberg FA, Burkman RT, Hagerty CG, Speroff L, Speroff T. Costs and net health effects of contraceptive methods. Contraception 2004;69:447-459.
57. Tay JL, Walker JJ. Ectopic pregnancy. BMJ 2000;320:916-919.
58. Toppozada HK, Koetsawang S, Aimakhu VE, Khan T, Pretnar-Darovec A, Chatterjee TK, Molitor-Peffer M-P, Apelo R, Lichtenberg R, Crosignani PG et al. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. WHO special programme of research, development and research training in human reproduction. Contraception 1983;28:1-20.
59. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Srewart F, Nelson A, Cates W, Guest F, Kowal D (eds). Contraceptive Technology: Eighteenth Revised Edition. New York, Ardent Media 2004;773-845.
60. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-72, 93.
61. Trussell J, Leveque JA, Koenig JD, London R, Borden S, Henneberry J, LaGuardia KD, Steward F, Wilson TG, Wysocki S et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health 1995;85:494-503.
62. United Nations. Department of Economic and Social Affairs. Population Division. World Contraceptive Use 2003. http://www.un.org/esa/population/ publications/contraceptive2003/wcu2003 (accessed on 17 September, 2006), 2003.
63. Varney SJ, Guest JF. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics 2004;22:1141-1151.
64. Westfall JM, Main DS, Barnard L. Continuation rates among injectable contraceptive users. Fam Plann Perspect 1996;28:275-277.
65. World Health Organization. Special Programme of Research, Development, Research Training in Human Reproduction. Task Force on the Safety and Efficacy of Fertility Regulating Methods. The TCu380A, TCu220C, multiload 250 and nova T IUDs at 3, 5 and 7 years of use - Results from three randomized multicentre trials. Contraception 1990;42:141-158.
66. Xiong X, Buekens P, Wollast E. IUD use and the risk of ectopic pregnancy: a meta-analysis of case-control studies. Contraception 1995;52:23-34.